
APPOINTMENT OF NON-EXECUTIVE DIRECTORS

Resonance Health Limited (**Resonance** or **Company**) (ASX: **RHT**) is pleased to announce the appointment of Mr Michael Sistenich and Dr David Fuller as Non-Executive Directors of the Company, effective immediately.

The appointments form part of the Company's ongoing Board renewal process and reflect its continued focus on strengthening Board capability to support the Company's strategic growth plans. The addition of Mr Sistenich and Dr Fuller enhances the Board's expertise across capital markets, healthcare technology, clinical development, and global commercialisation.

Mr Michael Sistenich

Mr Sistenich is an experienced ASX public company executive and Non-Executive Director with more than 25 years of global experience across healthcare, artificial intelligence, life sciences and institutional investing.

He is currently Chief Executive Officer and a Director of Enlitic, Inc. (ASX: ENL) (**Enlitic**), having previously served as its Non-Executive Chairman. At Enlitic, Mr Sistenich has led the Company's restructuring and recapitalisation, executed its initial public offering (**IPO**) on the Australian Securities Exchange (**ASX**), and overseen strategic acquisitions and global partnerships with leading healthcare and technology organisations.

Mr Sistenich has significant experience across medtech, healthcare AI and drug development. He previously served as Chief Executive Officer and Non-Executive Director of Nohla Therapeutics, where he led the development and financing of a clinical-stage cellular therapy platform. He has also served as a Non-Executive Director of Opthea Limited (ASX/Nasdaq: OPT), contributing to governance and oversight of late-stage clinical programs.

Mr Sistenich has extensive capital markets and investment banking experience, including as Director, Corporate Finance at Bell Potter Securities, where he led life sciences IPOs and capital raisings. He has also held senior investment roles at Lygon Capital Management, Meditor Capital Management and DWS Investments, managing global healthcare investment strategies and advising on private and public market transactions.

Mr Sistenich is a Founding Partner of Aurenda Partners, a corporate advisory firm focused on growth companies. He holds a Master of Science (Biochemistry) from the University of Oxford and is a CFA Charterholder.

Dr David Fuller

Dr Fuller is a highly experienced pharmaceutical physician and pharmacist with more than 30 years of international experience across drug development, clinical research, regulatory strategy and commercialisation.

He is currently Chief Medical Officer of Dimerix Limited (ASX: DXB), where he leads clinical development, regulatory engagement and medical strategy for the Company's renal-focused therapeutic programs.

Dr Fuller has extensive experience across the full drug development lifecycle, including pre-clinical development, Phase I–III clinical trials, regulatory approvals, product launches and post-marketing activities. He has successfully contributed to multiple regulatory submissions and approvals with major global agencies, including the US Food and Drug Administration (**FDA**) and European Medicines Agency (**EMA**), and has led programs resulting in commercialised products across oncology, renal medicine, neurology and anti-infectives.

His prior executive experience includes senior leadership roles at several ASX-listed and international biotechnology and pharmaceutical companies. These include Chief Medical Officer roles at Race Oncology (ASX: RAC), Aucentra Therapeutics and Arana Therapeutics (ASX-listed), as well as senior leadership roles at Syneos Health, where he was Senior Vice President, Clinical Development and responsible for the growth and strategic direction of the oncology business unit across Asia-Pacific.

Earlier in his career, Dr Fuller held senior roles at Genzyme (NASDAQ-listed) and Orphan Medical (NASDAQ-listed), where he played key roles in clinical development, regulatory approvals and product commercialisation. Notably, he contributed to the approval and launch of multiple therapies, including Busulfex®, Xyrem® and Renagel®, and has extensive experience in global clinical trial design and execution across the United States, Europe and Asia.

Dr Fuller has also held board and leadership roles across both listed and private companies, including Chairman of EpiAxis Therapeutics and prior Director roles at Adalta Ltd, Linear Clinical Research, and Dimerix Bioscience, where he was involved in transitioning the business from pre-clinical to clinical-stage development and its subsequent ASX listing.

Dr Fuller holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Sydney and a Bachelor of Pharmacy (First Class Honours) from the University of Sydney. He is a registered medical practitioner in Australia and the United Kingdom.

Board Renewal and Strategic Alignment

Resonance Health Chairperson, Mr Aaron Brinkworth commented:

“The appointment of Michael and David reflects Resonance Health’s commitment to ongoing Board renewal and ensuring the Company is well positioned to execute on its growth strategy.

Michael brings deep capital markets, medtech, and global healthcare capability, while David strengthens the Board’s clinical, regulatory, CRO, and clinical development experience.

Together, they significantly enhance the breadth of skills and experience across the Board as we continue to expand our global operations and advance our technology and product portfolio.”

Further Information: <https://investors.resonancehealth.com>

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information:

Andrew Harrison

Managing Director

E: andrewh@resonancehealth.com

P: +61 8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis

The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn.